Marrow transplantation in multiple myeloma

J. S. Tobias; J. D.M. Richards; Finn G. Wisløff; Stein A. Evensen; Jayesh Mehta; Arnon Nagler; Shimon Slavin; Gösta Gahrton; Bart Barlogie

doi:10.1056/NEJM199204163261613

Marrow transplantation in multiple myeloma

J. S. Tobias, J. D.M. Richards, Finn G. Wisløff, Stein A. Evensen, Jayesh Mehta, Arnon Nagler, Shimon Slavin, Gösta Gahrton, Bart Barlogie

Research output: Contribution to journal › Letter › peer-review

Abstract

To the Editor: In the study on multiple myeloma by the European Group for Bone Marrow Transplantation (Oct. 31 issue)¹ the principal component of treatment (in 81 of 90 patients) was total-body irradiation. Those involved in transplantation tend to forget that it is not the bone marrow transplant itself that has the potential to cure, but rather the conditioning regimen, the details of which are often only sketchily provided. The transplant itself provides the means for the patient to survive the supralethal bone marrow toxicity, with graft-versus-tumor effect probably playing a minor part. Does this matter? In our view, it.

Original language	English
Pages (from-to)	1086-1088
Number of pages	3
Journal	New England Journal of Medicine
Volume	326
Issue number	16
DOIs	https://doi.org/10.1056/NEJM199204163261613
State	Published - 16 Apr 1992
Externally published	Yes

Access to Document

10.1056/NEJM199204163261613

Cite this

@article{973246eb562d494f97dec5d61cee61ea,

title = "Marrow transplantation in multiple myeloma",

abstract = "To the Editor: In the study on multiple myeloma by the European Group for Bone Marrow Transplantation (Oct. 31 issue)1 the principal component of treatment (in 81 of 90 patients) was total-body irradiation. Those involved in transplantation tend to forget that it is not the bone marrow transplant itself that has the potential to cure, but rather the conditioning regimen, the details of which are often only sketchily provided. The transplant itself provides the means for the patient to survive the supralethal bone marrow toxicity, with graft-versus-tumor effect probably playing a minor part. Does this matter? In our view, it.",

author = "Tobias, {J. S.} and Richards, {J. D.M.} and Wisl{\o}ff, {Finn G.} and Evensen, {Stein A.} and Jayesh Mehta and Arnon Nagler and Shimon Slavin and G{\"o}sta Gahrton and Bart Barlogie",

year = "1992",

month = apr,

day = "16",

doi = "10.1056/NEJM199204163261613",

language = "English",

volume = "326",

pages = "1086--1088",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "16",

}

TY - JOUR

T1 - Marrow transplantation in multiple myeloma

AU - Tobias, J. S.

AU - Richards, J. D.M.

AU - Wisløff, Finn G.

AU - Evensen, Stein A.

AU - Mehta, Jayesh

AU - Nagler, Arnon

AU - Slavin, Shimon

AU - Gahrton, Gösta

AU - Barlogie, Bart

PY - 1992/4/16

Y1 - 1992/4/16

N2 - To the Editor: In the study on multiple myeloma by the European Group for Bone Marrow Transplantation (Oct. 31 issue)1 the principal component of treatment (in 81 of 90 patients) was total-body irradiation. Those involved in transplantation tend to forget that it is not the bone marrow transplant itself that has the potential to cure, but rather the conditioning regimen, the details of which are often only sketchily provided. The transplant itself provides the means for the patient to survive the supralethal bone marrow toxicity, with graft-versus-tumor effect probably playing a minor part. Does this matter? In our view, it.

AB - To the Editor: In the study on multiple myeloma by the European Group for Bone Marrow Transplantation (Oct. 31 issue)1 the principal component of treatment (in 81 of 90 patients) was total-body irradiation. Those involved in transplantation tend to forget that it is not the bone marrow transplant itself that has the potential to cure, but rather the conditioning regimen, the details of which are often only sketchily provided. The transplant itself provides the means for the patient to survive the supralethal bone marrow toxicity, with graft-versus-tumor effect probably playing a minor part. Does this matter? In our view, it.

UR - http://www.scopus.com/inward/record.url?scp=0026525353&partnerID=8YFLogxK

U2 - 10.1056/NEJM199204163261613

DO - 10.1056/NEJM199204163261613

M3 - Letter

C2 - 1549164

AN - SCOPUS:0026525353

SN - 0028-4793

VL - 326

SP - 1086

EP - 1088

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 16

ER -

Marrow transplantation in multiple myeloma

Abstract

Access to Document

Fingerprint

Cite this